MBX Biosciences appoints Steve Hoerter to board of directors

MBX Biosciences, Inc.

Steven L. Hoerter appointed as independent director effective April 7, 2025.
Board expanded from 8 to 9 members; Hoerter designated as Class III director until 2027 AGM.
Hoerter is former CEO of Deciphera Pharmaceuticals (acquired by Ono for $2.4B in 2024).
Brings 30+ years pharma commercialization experience; also serves on boards of ORIC Pharmaceuticals and C4 Therapeutics.
Will receive standard non-employee director compensation and enter indemnification agreement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven L. Hoerter

director

MBX · MBX Biosciences, Inc.

Effective: 2025-04-07
Filed: April 7, 2025, 7:59 PM ET

Effective as of April 7, 2025, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Steven L. Hoerter was appointed as director at MBX Biosciences, Inc..

Action: appointed
Role: director

Exact text from the filing

Effective as of April 7, 2025, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.

View on SEC.gov

MBX Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-051371

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.